UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

HemaSphere, 2022-06, Vol.6 (Suppl), p.1893-1894

2022

Volltextzugriff (PDF)

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

HemaSphere, 2023-05, Vol.7 (S2), p.27-28

2023

Volltextzugriff (PDF)

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐6 ARM‐A INTERIM ANALYSIS

HemaSphere, 2022-06, Vol.6 (Suppl), p.831-832

2022

Volltextzugriff (PDF)

Asymmetric reduction of ketones and β-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum

Applied microbiology and biotechnology, 2015-06, Vol.99 (12), p.5055-5069

2015

Volltextzugriff (PDF)

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1941-1955

2021

Volltextzugriff (PDF)

Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: Towards rational drug development for specific lymphoma subsets

Blood cells, molecules, & diseases, 2007-05, Vol.38 (3), p.199-203

2007

Volltextzugriff (PDF)

Rheology of potato starch chemically modified with microwave-assisted reactions

Food science & technology, 2013-09, Vol.53 (1), p.249-254

2013

Volltextzugriff (PDF)

Rationally Targeted, Conformationally Constrained, Oxetane-Modified Oligonucleotides Demonstrate Efficient Gene-Silencing Activity in a Cellular System

Annals of the New York Academy of Sciences, 2005-11, Vol.1058 (1), p.39-51

2005

Volltextzugriff (PDF)

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism

Journal of clinical oncology, 1997-05, Vol.15 (5), p.1885-1896

1997

Volltextzugriff (PDF)

DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Annals of oncology, 2019-10, Vol.30, p.v447

2019

Volltextzugriff (PDF)

1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Annals of oncology, 2019-10, Vol.30, p.v447-v447

2019

Volltextzugriff (PDF)

1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules

Nucleic acids research, 2004-01, Vol.32 (19), p.5791-5799

2004

Volltextzugriff (PDF)

Nucleic-acid therapeutics: basic principles and recent applications

Nature reviews. Drug discovery, 2002-07, Vol.1 (7), p.503-514

2002

Volltextzugriff (PDF)

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE‐AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM‐14

HemaSphere, 2022-06, Vol.6, p.1893-1894

2022

Volltextzugriff (PDF)

Transforming growth factor-beta signaling in normal and malignant hematopoiesis

Journal of interferon & cytokine research, 2007-07, Vol.27 (7), p.543-552

2007

Volltextzugriff (PDF)

Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

Hematology reports, 2020-09, Vol.12 (s1)

2020

Volltextzugriff (PDF)

Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)

Hematology reports, 2020-09, Vol.12 (s1)

2020

Volltextzugriff (PDF)

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics

Hematology reports, 2020-09, Vol.12 (s1)

2020

Volltextzugriff (PDF)

Asymmetric reduction of ketones and [beta]-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum

Applied microbiology and biotechnology, 2015-06, Vol.99 (12), p.5055

2015

Volltextzugriff (PDF)

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3003-3003

2011

Volltextzugriff (PDF)

High Resolution Epigenomic Profiling of Loss of Heterozygosity in MDS Reveals an Important Role of DNA Methylation in Regulating Expression of Genes in the Deleted Regions of Chromosomes 5q, 7q and 20q

Blood, 2007-11, Vol.110 (11), p.2120-2120

2007

Volltextzugriff (PDF)

Integrated Epigenomic Profiling Reveals Aberrant DNA Hypomethylation in LGL and Demonstrates That a Combination of Genetic and Epigenetic Events Results in Leukemic Evolution in Model of Large Granular Lymphocytic Leukemia

Blood, 2007-11, Vol.110 (11), p.2129-2129

2007

Volltextzugriff (PDF)

Global Epigenomic Profiling Demonstrates That Myelodysplasia Is Characterized by a Distinct Epigenetic Signature with Aberrant DNA Methylation Changes Involving Various Malignant and Hematopoietic Pathways

Blood, 2007-11, Vol.110 (11), p.2436-2436

2007

Volltextzugriff (PDF)

Global DNA Methylation Profiling Demonstrates That Idiopathic Myelofibrosis Is Characterized by a Distinct Epigenetic Signature with Aberrant Methylation Changes in Genes Involved in Inflammation and Hematopoiesis

Blood, 2007-11, Vol.110 (11), p.1536-1536

2007

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(76)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐6 ARM‐A INTERIM ANALYSIS

Asymmetric reduction of ketones and β-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: Towards rational drug development for specific lymphoma subsets

Rheology of potato starch chemically modified with microwave-assisted reactions

Rationally Targeted, Conformationally Constrained, Oxetane-Modified Oligonucleotides Demonstrate Efficient Gene-Silencing Activity in a Cellular System

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism

DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

1105TiP - DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules

Nucleic-acid therapeutics: basic principles and recent applications

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE‐AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM‐14

Transforming growth factor-beta signaling in normal and malignant hematopoiesis

Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics

Asymmetric reduction of ketones and [beta]-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study

High Resolution Epigenomic Profiling of Loss of Heterozygosity in MDS Reveals an Important Role of DNA Methylation in Regulating Expression of Genes in the Deleted Regions of Chromosomes 5q, 7q and 20q

Integrated Epigenomic Profiling Reveals Aberrant DNA Hypomethylation in LGL and Demonstrates That a Combination of Genetic and Epigenetic Events Results in Leukemic Evolution in Model of Large Granular Lymphocytic Leukemia

Global Epigenomic Profiling Demonstrates That Myelodysplasia Is Characterized by a Distinct Epigenetic Signature with Aberrant DNA Methylation Changes Involving Various Malignant and Hematopoietic Pathways

Global DNA Methylation Profiling Demonstrates That Idiopathic Myelofibrosis Is Characterized by a Distinct Epigenetic Signature with Aberrant Methylation Changes in Genes Involved in Inflammation and Hematopoiesis

Suchergebnisse filtern